{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-24-000041","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.613800+00:00","generated_at":"2026-05-31T13:00:29.063045+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xencor Q2 net loss widens to $66M; revenue falls 63% YoY to $17M","bullets":["Net loss $66.0M ($1.07 diluted EPS) vs $22.0M ($0.37) in Q2 2023; net loss $134M YTD.","Revenue $17.0M, down from $45.5M; primarily non-cash royalty and licensing; no J&J milestone.","Cash $585M as of June 30, down from $697M at Dec 31; FY2024 cash guidance $475-525M.","Regained exclusive worldwide rights to plamotamab (CD20 x CD3), a Phase 2-ready bispecific T-cell engager.","Vudalimab (PD-1 x CTLA-4) data update and advancement decision for mCRPC expected H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-24-000041","json":"https://secwatch.observer/filing/0001326732-24-000041.json","markdown":"https://secwatch.observer/filing/0001326732-24-000041.md","text":"https://secwatch.observer/filing/0001326732-24-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000041/0001326732-24-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000041/xncr-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:00:29.063045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}